Cormedix Inc.
A biopharmaceutical company that makes Defencath, a catheter lock solution used by kidney-dialysis patients to prevent bloodstream infections and blood clotting. Founded in 2006 by Antony P. Pfaffle, the firm began life as Picton Holding Company and was renamed CorMedix a few months later. The name blends the Latin "cor" (heart) with "medix," a nod to the medical conditions it addresses.
Granted 1.02M · Bought 75.4K
Sold 11.0K
Granted 1.00M · Bought 63.3K · Sold 80.0K
Granted 150.0K · Bought 57.0K
Granted 410.5K · Sold 194.0K
Granted 308.8K · Sold 50.0K
Granted 145.0K · Bought 496.5K
Bought 96.1K
Granted 28.0K · Bought 614.8K
Bought 160.0K
Granted 367.3K · Bought 199.1K · Sold 159.1K
Granted 142.5K
Granted 133.2K
Granted 112.5K · Bought 2.5K
Granted 36.1K · Bought 318.3K
Granted 112.5K · Bought 4.2K
Granted 86.7K · Bought 14.0K · Sold 30.0K
Granted 209.3K · Bought 151.3K · Sold 147.0K
Granted 68.8K
Granted 55.5K · Bought 10.0K
Bought 261.2K
Bought 10.0K
Sold 8.0K
Bought 1.2K
Bought 37.1K
Granted 40.0K · Sold 76.1K
Bought 130.2K
Bought 3.8K
Bought 17.0K
Granted 210.0K · Bought 2.0K · Sold 226.8K
Bought 10.0K
Bought 10.0K
Bought 1.0K
Granted 40.0K
Bought 7.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Gelbfish Gary A.Director · 11 transactions | — | 2.67Mas of Jan 2019 | 1.02M | 75.4K | — |
| Pharmabio Development Inc10% owner · 2 transactions | — | 778.6Kas of Apr 2012 | — | — | 11.0K |
| Todisco JosephChief Executive Officer, Director · 26 transactions | — | 774.7K | 1.00M | 63.3K | 80.0K |
| Milby RandyChief Executive Officer, Director · 25 transactions | — | 403.3Kas of Aug 2016 | 150.0K | 57.0K | — |
| Hurlburt ElizabethChief Operating Officer · 20 transactions | — | 278.5K | 410.5K | — | 194.0K |
| Zelnick Kaufman BethChief Legal Officer · 14 transactions | — | 269.1K | 308.8K | — | 50.0K |
| Kaplan MyronDirector · 31 transactions | — | 261.5K | 145.0K | 496.5K | — |
| Tellez Cora MDirector · 14 transactions | — | 182.4Kas of May 2017 | — | 96.1K | — |
| Khan MehmoodDirector · 16 transactions | — | 178.8Kas of Aug 2020 | 28.0K | 614.8K | — |
| Ellison Russell HDirector · 1 transaction | — | 160.0Kas of Mar 2010 | — | 160.0K | — |
| Lefkowitz Steven WDirector · 40 transactions | — | 158.1K | 367.3K | 199.1K | 159.1K |
| Blum SusanChief Financial Officer · 3 transactions | — | 142.5K | 142.5K | — | — |
| Seckler Michael DavidChief Commercial Officer · 1 transaction | — | 133.2K | 133.2K | — | — |
| Mistry ErinEVP, Chief Commercial Officer · 7 transactions | — | 101.0Kas of Jan 2025 | 112.5K | 2.5K | — |
| Armstrong Jr. John L.Exec VP of Tech Operations · 9 transactions | — | 96.9Kas of Jan 2021 | 36.1K | 318.3K | — |
| David Matthew TChief Financial Officer · 9 transactions | — | 95.3Kas of Jan 2025 | 112.5K | 4.2K | — |
| Dunton Alan WDirector · 11 transactions | — | 70.7K | 86.7K | 14.0K | 30.0K |
| Dillione JanetDirector · 27 transactions | — | 68.9K | 209.3K | 151.3K | 147.0K |
| Duncan Gregory ScottDirector · 3 transactions | — | 68.8K | 68.8K | — | — |
| Stewart Robert ADirector · 3 transactions | — | 66.5K | 55.5K | 10.0K | — |
| Baluch KhosoChief Executive Officer, Director · 9 transactions | — | 60.9Kas of Jan 2021 | — | 261.2K | — |
| Houser Mark T.Chief Medical Officer · 3 transactions | — | 52.8Kas of Nov 2010 | — | 10.0K | — |
| Masson-Hurlburt ElizabethEVP, Head of Clinical Ops · 1 transaction | — | 45.4Kas of Jan 2024 | — | — | 8.0K |
| Lefkowitz JamesDirector · 1 transaction | — | 40.3Kas of Dec 2011 | — | 1.2K | — |
| Markvicka TauniaDirector · 3 transactions | — | 37.1Kas of May 2017 | — | 37.1K | — |
| Duffy MatthewDirector · 7 transactions | — | 28.6Kas of Jun 2016 | 40.0K | — | 76.1K |
| Cook Robert W.Chief Financial Officer · 7 transactions | — | 27.5Kas of Sep 2019 | — | 130.2K | — |
| Houghton John C.President and CEO, Director · 2 transactions | — | 17.3Kas of Aug 2010 | — | 3.8K | — |
| Lenz BrianCFO, TREASURER & SECRETARY · 4 transactions | — | 17.0Kas of Dec 2011 | — | 17.0K | — |
| Pfaffle AntonyChief Scientific Officer · 47 transactions | — | 10.0Kas of Feb 2017 | 210.0K | 2.0K | 226.8K |
| Costa Paulo FDirector · 1 transaction | — | 10.0Kas of May 2023 | — | 10.0K | — |
| George Michael WDirector · 1 transaction | — | 10.0Kas of May 2017 | — | 10.0K | — |
| Hofer Timothy MDirector · 1 transaction | — | 8.4Kas of Dec 2011 | — | 1.0K | — |
| Masson ElizabethEVP, Head of Clinical Ops. · 1 transaction | — | 8.0Kas of Feb 2020 | 40.0K | — | — |
| Mounts PhoebeGeneral Counsel · 3 transactions | — | 7.2Kas of Jan 2023 | — | 7.2K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +1.77M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.